UCLA SPORE in Prostate Cancer

加州大学洛杉矶分校前列腺癌孢子项目是一个多学科和转化性的研究项目，其目的是了解前列腺癌的生物学，并开发更有效的预防、诊断和治疗方法。这项任务将通过(1)五个主要研究项目来完成，这些项目侧重于将基础和人口科学应用于前列腺癌的预防、诊断和治疗，以及(2)通过职业发展和发展研究项目招募和发展新的前列腺癌研究人员和研究项目。加州大学洛杉矶分校的前列腺孢子利用加州大学洛杉矶分校、其姊妹机构以及锡达斯·西奈和希望之城癌症中心令人兴奋的资源和计划来改善前列腺癌男性的护理。它与其他孢子机构和NCI的孢子计划广泛合作，以推动地方和国家的倡议。在最初四年的资助中，加州大学洛杉矶分校的孢子取得了重大进展，例如PSCA抗体疗法的开发和临床应用，在分子水平上证明mTOR拮抗剂下调了PTEN缺失肿瘤患者的PIS激酶-PTEN-Akt通路，并在接受前列腺手术的男性患者中启动了一项新的饮食预防试验。在本申请中，五个主要项目如下：1)项目1：用于前列腺癌成像的针对前列腺干细胞抗原(PSCA)的生物工程抗体(项目负责人：Anna Wu，M.D.和Robert Reiter，M.D.；项目共同负责人Robert Figlin，M.D.)；2)项目2：前列腺癌的PIS途径抑制疗法(项目负责人：Hong Wu，M.D.，Ph.D.和Charles Sawyers，M.D.；项目共同负责人Robert Reiter，M.D.和Howard Scher，M.D.；3)项目3：前列腺癌中的淋巴管生成和转移(项目负责人：莉莉·吴，医学博士；项目共同负责人：David Agus，M.D.)；4)项目4：评估IGFBP-3疗法在前列腺癌男性患者中的作用(项目负责人：Pinchas Cohen，M.D.；项目共同负责人：Alan Pantuck，M.D.和Kuk-Wha Lee，M.D.，Ph.D.；5)项目5：前列腺癌预防的膳食脂肪调节和靶向治疗(项目负责人：William Aronson，M.D.；项目联合负责人：Pinchas Cohen医学博士和Harvey Herschman博士)

The UCLA Prostate Cancer SPORE program is a multidisciplinary and translational research program whose purpose is to understand the biology of prostate cancer and to develop more effective methods for prevention, diagnosis and treatment. This mission will be accomplished through (1) five major research projects focused on the application of basic and population science to the prevention, diagnosis and treatment of prostate cancer, and (2) the recruitment and development of new prostate cancer researchers and research projects through career development and developmental research projects. The UCLA prostate SPORE leverages the exciting resources and programs at UCLA, its sister institutions, as well as Cedars Sinai and City of Hope Cancer Center, to improve the care of men with prostate cancer. It collaborates extensively with other SPORE institutions and the SPORE program at the NCI to advance local and national initiatives. Over the first four years of funding, the UCLA SPORE has made significant strides, such as the development and translation of PSCA antibody therapy to the clinic, the demonstration at the molecular level that mTOR antagonism down-regulates the PIS kinase-PTEN-Akt pathway in men with PTEN null tumors, and the initiation of a novel dietary prevention trial in men undergoing prostate surgery. In this application, the five major projects are as follows: 1) Project 1: Bioengineered Antibodies Against Prostate Stem Cell Antigen (PSCA) for Prostate Cancer Imaging (Project Leaders: Anna Wu, M.D. and Robert Reiter, M.D; Project co-Leader, Robert Figlin, M.D.); 2) Project 2: Exploiting PIS Pathway Inhibitor Therapy in Prostate Cancer (Project Leaders: Hong Wu, M.D, Ph.D. and Charles Sawyers, M.D; Project co-Leaders, Robert Reiter, M..D. and Howard Scher, M.D; 3) Project 3: Lymphangiogenesis and Metastasis in Prostate Cancer (Project Leader: Lily Wu, M.D., Ph.D; Project co-Leader: David Agus, M.D.); 4) Project 4: Evaluating the role of IGFBP-3 therapy in men with prostate cancer (Project Leader: Pinchas Cohen, M.D.; Project co- Leaders: Alan Pantuck, M.D and Kuk-Wha Lee, M.D., Ph.D; 5) Project 5: Dietary Fat Modulation and targeted Therapies for Prostate Cancer Prevention (Project Leader: William Aronson, M.D.; Project co- Leaders: Pinchas Cohen, M.D. and Harvey Herschman, Ph.D.)